PMID- 22246824
OWN - NLM
STAT- MEDLINE
DCOM- 20120613
LR  - 20221207
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
VI  - 84
IP  - 3
DP  - 2012 Mar
TI  - An in-house HIV genotyping assay for the detection of drug resistance mutations 
      in Southeast Asian patients infected with HIV-1.
PG  - 394-401
LID - 10.1002/jmv.23202 [doi]
AB  - Genotyping for HIV drug resistance is costly and beyond the means for many 
      Southeast Asian patients, who are self-funded. This prompted the development of a 
      more cost-effective, in-house assay for an ethnically diverse, Southeast Asian 
      population at the National University Hospital in Singapore, using Sanger-based 
      sequencing. Plasma samples from 20 treatment-failure patients with a broad 
      spectrum of HIV drug resistance mutations were used to validate this assay 
      clinically. Blinded testing gave concordant results for 7/7 (100%) protease drug 
      resistance-related mutations, including one major and six minor mutations, and 
      111/116 (95.7%) reverse-transcriptase (RT) drug resistance-related mutations, 
      including 65 nucleoside RT inhibitors (NRTI) and 46 non-nucleoside RT inhibitors 
      (NNRTI) mutations. There were five discordant results, involving three NRTI- and 
      two NNRTI-resistance-associated mutations. Highly conserved primers designed to 
      have a wide coverage of the HIV pol gene (covering the entire protease and 395 
      codons of the RT region) enabled efficient multi-ethnic population-based 
      genotyping. Reagents for this in-house test cost around 60% less than those for 
      commercially available assays (SGD150 vs. SGD350 per sample). In addition, this 
      assay also identified mutations located within the C-terminal domain (codons 
      312-560) of RT that are beyond the reach of most published and commercial GRTs. 
      Currently, most research on C-terminal drug-resistance-related mutations has been 
      conducted on HIV subtype B infections. Therefore this assay enables further study 
      of these C-terminal mutations in Southeast Asian populations, where there is a 
      high prevalence of CRF01_AE and other non-subtype B HIV infections.
CI  - Copyright (c) 2012 Wiley Periodicals, Inc.
FAU - Lee, Chun Kiat
AU  - Lee CK
AD  - Molecular Diagnosis Centre, Department of Laboratory Medicine, National 
      University Hospital, Singapore, Singapore.
FAU - Lee, Hong Kai
AU  - Lee HK
FAU - Loh, Tze Ping
AU  - Loh TP
FAU - Sethi, Sunil Kumar
AU  - Sethi SK
FAU - Koay, Evelyn Siew-Chuan
AU  - Koay ES
FAU - Tang, Julian Wei-Tze
AU  - Tang JW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (Anti-HIV Agents)
RN  - EC 2.7.7.49 (HIV Reverse Transcriptase)
RN  - EC 3.4.23.- (HIV Protease)
SB  - IM
MH  - Anti-HIV Agents/*pharmacology/therapeutic use
MH  - Asian People
MH  - Drug Resistance, Viral/genetics
MH  - Genotype
MH  - *Genotyping Techniques
MH  - HIV Infections/diagnosis/drug therapy/virology
MH  - HIV Protease/genetics
MH  - HIV Reverse Transcriptase/genetics
MH  - HIV-1/*drug effects/*genetics
MH  - Humans
MH  - *Mutation
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Viral Load
EDAT- 2012/01/17 06:00
MHDA- 2012/06/14 06:00
CRDT- 2012/01/17 06:00
PHST- 2012/01/17 06:00 [entrez]
PHST- 2012/01/17 06:00 [pubmed]
PHST- 2012/06/14 06:00 [medline]
AID - 10.1002/jmv.23202 [doi]
PST - ppublish
SO  - J Med Virol. 2012 Mar;84(3):394-401. doi: 10.1002/jmv.23202.